247 related articles for article (PubMed ID: 27577068)
1. Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.
Shen C; Peng C; Shen B; Zhu Z; Xu N; Li T; Xie J
Oncotarget; 2016 Sep; 7(38):62647-62656. PubMed ID: 27577068
[TBL] [Abstract][Full Text] [Related]
2. Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation.
Zhang Q; Deng YL; Liu C; Huang LH; Shang L; Chen XG; Wang LT; Du JZ; Wang Y; Wang PX; Zhang H; Shen ZY
World J Gastroenterol; 2016 Nov; 22(43):9571-9585. PubMed ID: 27920478
[TBL] [Abstract][Full Text] [Related]
3. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
5. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
[TBL] [Abstract][Full Text] [Related]
7. Metformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivo.
Zhang HH; Zhang Y; Cheng YN; Gong FL; Cao ZQ; Yu LG; Guo XL
Mol Carcinog; 2018 Jan; 57(1):44-56. PubMed ID: 28833603
[TBL] [Abstract][Full Text] [Related]
8. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
Zhou J; Fan J; Wang Z; Wu ZQ; Qiu SJ; Huang XW; Yu Y; Sun J; Xiao YS; He YF; Wang YQ; Tang ZY
World J Gastroenterol; 2006 May; 12(19):3114-8. PubMed ID: 16718799
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
Zimmerman MA; Trotter JF; Wachs M; Bak T; Campsen J; Skibba A; Kam I
Liver Transpl; 2008 May; 14(5):633-8. PubMed ID: 18324656
[TBL] [Abstract][Full Text] [Related]
10. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
Cholongitas E; Mamou C; Rodríguez-Castro KI; Burra P
Transpl Int; 2014 Oct; 27(10):1039-49. PubMed ID: 24943720
[TBL] [Abstract][Full Text] [Related]
12. [A retrospective cohort study regarding the effect of sirolimus-based immunosuppression protocol on the long-term survival of hepatocellular carcinoma patients after liver transplantation].
Zhao X; Lu S; Wang M; Wu J; Lin D; Guo Q; Lai W; Zeng D; Li C; Liu Y; Sun L; Yan D; Li N
Zhonghua Wai Ke Za Zhi; 2014 Apr; 52(4):245-8. PubMed ID: 24924566
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence.
Jung DH; Tak E; Hwang S; Song GW; Ahn CS; Kim KH; Moon DB; Ha TY; Park GC; Ryoo BY; Lee KJ; Kim N; Kwon JH; Jwa EK; Lee SG
Liver Transpl; 2018 Jul; 24(7):932-945. PubMed ID: 29710388
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
[TBL] [Abstract][Full Text] [Related]
15. Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma.
Kawahara T; Toso C; Yamaguchi K; Cader S; Douglas DN; Nourbakhsh M; Lewis JT; Churchill TA; Yagita H; Kneteman NM
Liver Int; 2013 Oct; 33(9):1441-8. PubMed ID: 23895107
[TBL] [Abstract][Full Text] [Related]
16. Targeting AMPK, mTOR and β-Catenin by Combined Metformin and Aspirin Therapy in HCC: An Appraisal in Egyptian HCC Patients.
Abdelmonsif DA; Sultan AS; El-Hadidy WF; Abdallah DM
Mol Diagn Ther; 2018 Feb; 22(1):115-127. PubMed ID: 29094287
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.
Zheng L; Yang W; Wu F; Wang C; Yu L; Tang L; Qiu B; Li Y; Guo L; Wu M; Feng G; Zou D; Wang H
Clin Cancer Res; 2013 Oct; 19(19):5372-80. PubMed ID: 23942093
[TBL] [Abstract][Full Text] [Related]
18. Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma.
Viganò M; Bhoori S; Lampertico P; Donato MF; Iavarone M; Grossi G; Facciorusso A; Caccamo L; Rossi G; Colombo M; Mazzaferro V
Liver Int; 2015 Sep; 35(9):2187-93. PubMed ID: 25809541
[TBL] [Abstract][Full Text] [Related]
19. Metformin-associated Chemopreventive Effects on Recurrence After Hepatic Resection of Hepatocellular Carcinoma: From
Kang WH; Tak E; Hwang S; Song GW; Jwa E; Lee YJ; Kim KH; Ahn CS; Moon DB; Ha TY; Jung DH; Park GC; Lee KJ; Kim N; Lee SG
Anticancer Res; 2018 Apr; 38(4):2399-2407. PubMed ID: 29599368
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria.
Ye Q; Ling S; Jiang G; Shan Q; Xu S; Zhan Q; Wu Y; Liu Y; Zheng S; Xu X
Eur J Surg Oncol; 2021 Oct; 47(10):2533-2542. PubMed ID: 33902956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
